Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 16/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223561 | 0.86 | ADRA1A (0.47) | ADRA1AADRA1BADRA1DADAM17 | |
| SCHEMBL8221705 | 0.79 | CKS1B (0.48) | ADRA1AADRA1BADRA1D | |
| SCHEMBL8275877 | 0.75 | ADAM17 (0.49) | ADAM17CHRM4 | |
| SCHEMBL8224076 | 0.74 | ADAM17 (0.39) | ADRA1AADRA1BADRA1DADAM17 | |
| SCHEMBL8221977 | 0.73 | ADAM17 (0.48) | ADAM17CHRM4SCN5ASCN9A | |
| SCHEMBL8221438 | 0.73 | ADAM17 (0.53) | ADAM17CHRM4SCN5ASCN9A | |
| SCHEMBL8221453 | 0.73 | ADAM17 (0.53) | ADAM17CHRM4SCN5ASCN9A | |
| SCHEMBL8273348 | 0.73 | ADAM17 (0.53) | ADAM17CHRM4SCN5ASCN9A | |
| SCHEMBL12215263 | 0.73 | ADAM17 (0.51) | ADAM17CHRM4SCN5ASCN9A | |
| SCHEMBL8223487 | 0.72 | ADRA1A (0.48) | ADRA1AADRA1BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |